Your browser doesn't support javascript.
loading
[Clinical Analysis of 24 Acute myeloid Leukemia Patients Aged -over 80 Years].
Meng, Guang-Qiang; Chen, Yi-Juan; Guo, Hui-Xia; Wang, Min; Wu, Yue; Li, Xing; Shang, Yu-Xi; Li, Qian; Wang, Li-Ru.
Afiliación
  • Meng GQ; Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
  • Chen YJ; Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
  • Guo HX; Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
  • Wang M; Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
  • Wu Y; Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
  • Li X; Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
  • Shang YX; Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
  • Li Q; Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
  • Wang LR; Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China.E-mail:wanglirumail@126.com.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 27(1): 33-38, 2019 Feb.
Article en Zh | MEDLINE | ID: mdl-30738444
ABSTRACT

OBJECTIVE:

To investigate the clinical features of acute myeloid leukemia patients aged over 80 years.

METHODS:

The clinical data from 24 cases of acute myeloid leukemia (non-M3) aged over 80 years were analyzed retrospectively. Clinical characteristics, therapeutic efficacy and overall survival rate of the patients received low dose chemotherapy and/or decitabine were compared with that received only supportive care.

RESULTS:

According to FAB classification, the 10 patients were M2 subtypes (41.7%), the 7 patients were M4 subtypes (29.2%), the 4 patiens were M5 (16.7%), the 3 patients were unclassifed (16.5%). 22 patients (91.0%) were complicated with underling diseases. Among 13 patients received low dose chemotherapy or decitabine, 8 cases (61.5%) achived partial remission or higher remission. The median survival time of patients who reseived chemotherapy was 30 weeks, and signicantly longer than that of patients received supportive care (median survival time was 9 weeks (P<0.05)). The univariated analysis showed that WBC≥50×109/L, ECOG≥2 and received supportive care were unfavonrable prognostic factors for overall survival.

CONCLUSION:

More than half of patients aged over 80 years who received individudized treatment can achieve partial remission or higher remission, and can have more longer survival time..
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda Tipo de estudio: Observational_studies / Prognostic_studies Límite: Aged80 / Humans Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda Tipo de estudio: Observational_studies / Prognostic_studies Límite: Aged80 / Humans Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: China